Jack Zakrzewski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jack Zakrzewski has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Ankit Indravadan Mehta
University of Illinois at Chicago
7 shared publications - Abhiraj D. Bhimani
Department of Neurosurgery, University of Illinois at Chicago, Chicago, Illinois, USA
4 shared publications Darian R. Esfahani
Department of Neurosurgery, University of Illinois at Chicago, Chicago, Illinois, USA
4 shared publicationsPouyan Kheirkhah
Department of Neurosurgery, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA
4 shared publications- Steven Denyer
Department of Neurosurgery, University of Illinois at Chicago, Chicago, Illinois, USA
4 shared publications Saavan Patel
Department of Neurosurgery, The University of Illinois at Chicago, Chicago, Illinois, USA
3 shared publications
Latest Publications
- 9 October 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 121 (6) , 1471-1477
Earlier Fontan Candidacy Determination: A Focus on Anatomic and Physiologic Variables
- 9 October 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 121 (6) , 1471-1477
Earlier Fontan Candidacy Determination: A Focus on Anatomic and Physiologic Variables
- 17 November 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 228, 279-286
Prolonged travel time to transplantation center is associated with poor outcomes following heart transplantation
- 17 November 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 228, 279-286
Prolonged travel time to transplantation center is associated with poor outcomes following heart transplantation
- 31 August 2022
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 68 (9) , e157
Response to Muller et al. Regarding “Impact of COVID-19 on Patients Supported with a Left Ventricular Assist Device”
- 31 August 2022
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 68 (9) , e157
Response to Muller et al. Regarding “Impact of COVID-19 on Patients Supported with a Left Ventricular Assist Device”
- 1 September 2021
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 67 (11) , 1189-1195
Impact of COVID-19 on Patients Supported with a Left Ventricular Assist Device
Patients on left ventricular assist device (LVAD) support may be susceptible to severe disease and complications from coronavirus disease-19 (COVID-19). The purpose of this study was to describe the clinical course of COVID-19 in LVAD patients. A retrospective review was performed at our center; 28 LVAD patients who developed COVID-19 between March 2020 and March 2021, and six patients with a prior COVID-19 infection who underwent LVAD implantation, were identified and examined. Of the 28 patients, nine (32%) died during the study period, five (18%) during their index hospitalization for COVID-19. Two patients (7%) presented with suspected pump thrombosis. In a nonadjusted binary regression logistic analysis, admission to the intensive care unit (unadjusted odds ratio, 7.6 [CI, 1.2–48], P = 0.03), and the need for mechanical ventilation (unadjusted odds ratio 14 [CI, 1.3–159], P = 0.03) were associated with mortality. The six patients who previously had COVID-19 and subsequently received a LVAD were on intra-aortic balloon pump and inotropic support at time of surgery. All six experienced a complicated and prolonged postoperative course. Three patients (50%) suffered from ischemic stroke, and there was one (17%) 30 day mortality. We observed an increased risk of morbidity and mortality in LVAD patients with COVID-19.
- 1 September 2021
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 67 (11) , 1189-1195
Impact of COVID-19 on Patients Supported with a Left Ventricular Assist Device
Patients on left ventricular assist device (LVAD) support may be susceptible to severe disease and complications from coronavirus disease-19 (COVID-19). The purpose of this study was to describe the clinical course of COVID-19 in LVAD patients. A retrospective review was performed at our center; 28 LVAD patients who developed COVID-19 between March 2020 and March 2021, and six patients with a prior COVID-19 infection who underwent LVAD implantation, were identified and examined. Of the 28 patients, nine (32%) died during the study period, five (18%) during their index hospitalization for COVID-19. Two patients (7%) presented with suspected pump thrombosis. In a nonadjusted binary regression logistic analysis, admission to the intensive care unit (unadjusted odds ratio, 7.6 [CI, 1.2–48], P = 0.03), and the need for mechanical ventilation (unadjusted odds ratio 14 [CI, 1.3–159], P = 0.03) were associated with mortality. The six patients who previously had COVID-19 and subsequently received a LVAD were on intra-aortic balloon pump and inotropic support at time of surgery. All six experienced a complicated and prolonged postoperative course. Three patients (50%) suffered from ischemic stroke, and there was one (17%) 30 day mortality. We observed an increased risk of morbidity and mortality in LVAD patients with COVID-19.
- 1 November 2020
- Published by Elsevier in World Neurosurgery
- Vol. 143, e648-e655
Concurrent Versus Staged Procedures for Ventriculoperitoneal Shunt and Cranioplasty: A 10-Year Retrospective Comparative Analysis of Surgical Outcomes
- 1 November 2020
- Published by Elsevier in World Neurosurgery
- Vol. 143, e648-e655
Concurrent Versus Staged Procedures for Ventriculoperitoneal Shunt and Cranioplasty: A 10-Year Retrospective Comparative Analysis of Surgical Outcomes
- 1 November 2019
- Published by Elsevier in World Neurosurgery
- Vol. 131, e312-e320
Autologous Bone Cranioplasty: A Retrospective Comparative Analysis of Frozen and Subcutaneous Bone Flap Storage Methods
- 1 November 2019
- Published by Elsevier in World Neurosurgery
- Vol. 131, e312-e320
Autologous Bone Cranioplasty: A Retrospective Comparative Analysis of Frozen and Subcutaneous Bone Flap Storage Methods
- 1 September 2018
- Published by Elsevier in World Neurosurgery
- Vol. 117, e290-e299
Surgical Complications in Intradural Extramedullary Spinal Cord Tumors - An ACS-NSQIP Analysis of Spinal Cord Level and Malignancy
- 1 September 2018
- Published by Elsevier in World Neurosurgery
- Vol. 117, e290-e299
Surgical Complications in Intradural Extramedullary Spinal Cord Tumors - An ACS-NSQIP Analysis of Spinal Cord Level and Malignancy
- 1 August 2018
- Published by Elsevier in World Neurosurgery
- Vol. 116, e525-e533
Location of Thalamic Hemorrhage Impacts Prognosis
- 1 August 2018
- Published by Elsevier in World Neurosurgery
- Vol. 116, e525-e533
Location of Thalamic Hemorrhage Impacts Prognosis
- Open Access
- 30 July 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 11417
Magnetic Drug Targeting: A Novel Treatment for Intramedullary Spinal Cord Tumors
Most applications of nanotechnology in cancer have focused on systemic delivery of cytotoxic drugs. Systemic delivery relies on accumulation of nanoparticles in a target tissue through enhanced permeability of leaky vasculature and retention effect of poor lymphatic drainage to increase the therapeutic index. Systemic delivery is limited, however, by toxicity and difficulty crossing natural obstructions, like the blood spine barrier. Magnetic drug targeting (MDT) is a new technique to reach tumors of the central nervous system. Here, we describe a novel therapeutic approach for high-grade intramedullary spinal cord tumors using magnetic nanoparticles (MNP). Using biocompatible compounds to form a superparamagnetic carrier and magnetism as a physical stimulus, MNP-conjugated with doxorubicin were successfully localized to a xenografted tumor in a rat model. This study demonstrates proof-of-concept that MDT may provide a novel technique for effective, concentrated delivery of chemotherapeutic agents to intramedullary spinal cord tumors without the toxicity of systemic administration.
- 30 July 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 11417
Open AccessMagnetic Drug Targeting: A Novel Treatment for Intramedullary Spinal Cord Tumors
Most applications of nanotechnology in cancer have focused on systemic delivery of cytotoxic drugs. Systemic delivery relies on accumulation of nanoparticles in a target tissue through enhanced permeability of leaky vasculature and retention effect of poor lymphatic drainage to increase the therapeutic index. Systemic delivery is limited, however, by toxicity and difficulty crossing natural obstructions, like the blood spine barrier. Magnetic drug targeting (MDT) is a new technique to reach tumors of the central nervous system. Here, we describe a novel therapeutic approach for high-grade intramedullary spinal cord tumors using magnetic nanoparticles (MNP). Using biocompatible compounds to form a superparamagnetic carrier and magnetism as a physical stimulus, MNP-conjugated with doxorubicin were successfully localized to a xenografted tumor in a rat model. This study demonstrates proof-of-concept that MDT may provide a novel technique for effective, concentrated delivery of chemotherapeutic agents to intramedullary spinal cord tumors without the toxicity of systemic administration.